ORR up to 100%, median overall survival doubled: CAR-T breaks through late-line liver cancer

▤ Summary

Ori-C101, a GPC3-targeted CAR-T therapy from Yuanqi Biotech, has advanced into phase II testing for late-line hepatocellular carcinoma in China. The article highlights strong phase I results, including an ORR of 66.7% at the recommended phase 2 dose and 100% in the highest dose cohort, along with a median overall survival of 21.4 months. It also explains the therapy’s design choices around antibody selection, armored elements, and manufacturing process improvements. The piece positions GPC3 as a promising target and frames CAR-T as a potential treatment option for patients with few remaining alternatives.

▦ Linked Companies